Used in the treatment of advanced solid tumors, this antibody targets the CD40 receptor to activate antigen-presenting cells, enhancing anti-tumor immune responses. It acts as an immune agonist, stimulating dendritic cells to promote T-cell activation and tumor cell destruction. Currently investigated in clinical trials, it is being evaluated both as a monotherapy and in combination with checkpoint inhibitors like anti-PD-1 agents to improve outcomes in cancers such as pancreatic, colorectal, and non-small cell lung cancer. Its mechanism supports potential use in overcoming resistance to existing immunotherapies.